Compare FEIM & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEIM | AUTL |
|---|---|---|
| Founded | 1961 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 439.6M | 407.2M |
| IPO Year | 1994 | 2025 |
| Metric | FEIM | AUTL |
|---|---|---|
| Price | $68.32 | $1.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $51.50 | $8.50 |
| AVG Volume (30 Days) | 143.8K | ★ 1.6M |
| Earning Date | 03-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 316.95 | N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $69,811,000.00 | $10,120,000.00 |
| Revenue This Year | N/A | $80.32 |
| Revenue Next Year | $21.73 | $53.96 |
| P/E Ratio | $176.63 | ★ N/A |
| Revenue Growth | 26.30 | ★ 496.00 |
| 52 Week Low | $18.63 | $1.18 |
| 52 Week High | $76.07 | $2.70 |
| Indicator | FEIM | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 56.28 | 44.26 |
| Support Level | $43.53 | $1.27 |
| Resistance Level | $76.07 | $1.73 |
| Average True Range (ATR) | 5.11 | 0.14 |
| MACD | 0.10 | -0.02 |
| Stochastic Oscillator | 62.83 | 7.87 |
Frequency Electronics Inc is engaged in the design, development, and manufacture of high-precision timing, and frequency control products for space, air, sea, and terrestrial applications. The company has FEI-NY and FEI-Zyfer reportable segments. It derives the majority of its revenues from the FEI-NY segment. FEI-NY segment operations consist principally of precision time and frequency control products used in three principal markets namely communication satellites (both commercial and U.S. Government-funded); terrestrial cellular telephone or other ground-based telecommunication stations; and other components and systems for the U.S. military.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.